Valley Bank and Bluevine leaders discuss distinct M&A integration
Valley Bank's COO said the Bluevine deal brings unique aspects compared to typical bank M&A. This signals new challenges and approaches for regulated firms considering similar deals. Executives should watch for further details on integration strategies.
UMB to acquire El Dorado Savings Bank in $506M deal
UMB will buy California-based El Dorado Savings Bank for $506 million, according to Banking Dive. The CEO said more M&A could follow, but only if UMB retains board control. Senior leaders should watch for further consolidation moves.
Thrive Holdings buys ADT for $15.3 billion to expand AI in home security
Thrive Holdings, backed by OpenAI, has acquired ADT for $15.3 billion. The deal signals a push to bring advanced AI into physical security, a sector relevant to insurers and tech firms. Watch for new AI-powered security products and changing industry alliances.
Vertex kidney drug faces scrutiny over infection risk before FDA decision
Vertex’s kidney disease drug is under heavy scrutiny for infection risk ahead of a key FDA approval decision on 30 November. Senior pharma leaders should note the regulatory focus on safety. The outcome may affect future drug approvals and market entry strategies.
Biopharma firms split over Treasury’s China rule exemption
A proposed Treasury rule has sparked debate in the biopharma sector over an exemption for certain deals with China. Senior pharma leaders face regulatory uncertainty affecting cross-border collaborations. Companies should assess deal structures and monitor rule changes.
US rule orders pharmacy benefit managers to reveal secret payments
A new US rule will require pharmacy benefit managers to disclose previously hidden fees and compensation. This change could affect pricing and transparency for health insurers and pharma companies. Firms should prepare for possible shifts in contract terms and regulatory scrutiny.
FDA scientists resisted White House plan to ease rules on peptide drugs
A White House-backed plan to relax FDA oversight on peptide drugs met resistance from FDA scientists, according to Fast Company. Senior leaders in pharma and healthcare face regulatory uncertainty as internal divisions emerge. Watch for final policy decisions from the FDA.
Lilly says new diabetes drug outperforms Ozempic in major study
Eli Lilly reported its experimental drug retatrutide surpassed Novo Nordisk’s Ozempic in reducing blood sugar and weight. This raises competitive pressure in diabetes care, a key market for pharma leaders. Watch for regulatory and payer responses.
Capital One uses AI to cut audit errors by 85% and speed fraud checks
Capital One has reduced quality errors in audit risk and compliance by 85% using AI, according to MIT Sloan Management Review. The bank also saves thousands of audit hours and improves customer service with generative AI. Senior leaders should assess how enterprise AI can deliver measurable operational gains.
Ripple wins OCC charter and expands with BNY, Robinhood partnerships
Ripple received an unconditional charter from the OCC and is now expanding partnerships with BNY and Robinhood. This move signals growing regulatory acceptance for fintechs in banking. Senior executives should watch for further integration with major financial players.
PNC CEO shifts focus from M&A to AI investment for cost savings
PNC CEO Bill Demchak said the bank will prioritise AI over mergers and acquisitions, with planned spending in the hundreds of millions to save billions. Senior leaders should note the shift in capital allocation and its impact on deal activity and technology priorities.
Bristol Myers faces safety issue after patient death from autoimmune CAR-T therapy
A patient died 44 days after receiving Bristol Myers' zola-cel therapy, according to BioPharma Dive. Gilead has also acquired a company for nearly $1.3 billion to compete with J&J's psoriasis pill. Pharma leaders must weigh safety risks and market shifts.
PwC says ransomware actor accessed learning records via vendor breach
PwC confirmed a ransomware actor accessed its learning records through a vendor site, according to Cybersecurity Dive. This raises concerns for regulated-industry leaders about third-party cyber risks. Firms may need to review their vendor oversight and incident response plans.
Bon Secours Mercy Health buys surgery centre chain in $5.7 billion deal
Bon Secours Mercy Health plans a $5.7 billion acquisition of a surgery centre chain, according to STAT. The move would make it one of the largest outpatient surgery operators. Hospital and insurer leaders should watch for shifts in referral patterns and pricing.
US court rejects Federal Reserve’s debit card fee cap
A US appellate court ruled the Federal Reserve’s debit card interchange rule fails to meet Congress’s intent for swipe fee limits. The decision could affect payment costs and compliance for banks and card issuers. Watch for regulatory or industry responses.
Turkiye Sigorta shares fall 18% as CEO and deputy arrested in fund probe
Turkiye Sigorta’s CEO and deputy were arrested amid a market manipulation probe, sending shares down 18% in two days. The case raises governance and risk questions for insurance leaders. Watch for regulatory fallout and further market disruption.
Epic says payers race to meet prior authorisation tech deadline
Epic’s Ryan Bohochik says payers are moving to adopt new prior authorisation technology before the January 1 deadline. This affects how quickly providers and insurers can process approvals. Leaders should monitor compliance and readiness across their networks.
Artiva shuts autoimmune cell therapy trial after two patient deaths
Artiva is ending its autoimmune cell therapy trial following two patient deaths, according to STAT. This setback raises concerns for drugmakers seeking to adapt cancer therapy methods to autoimmune diseases. Companies should review risk protocols and trial oversight.
US House investigates PBMs over audits of independent pharmacies
A House lawmaker is examining whether the three largest PBMs carried out retaliatory audits on independent pharmacies. The probe could affect how PBMs manage pharmacy relationships and compliance. Leaders should monitor for regulatory changes affecting supply chain control.
Euronet and Fireblocks extend partnership to support stablecoin-funded cards
Euronet and Fireblocks are working together to offer infrastructure for stablecoin-funded cards, according to Payments Dive. This move could allow banks and payment firms to offer new digital asset services. Senior leaders should assess operational and regulatory implications.